BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...five obesity programs, Novo pins hopes on amylin/GLP-1...
...for obesity with the pick of an amylin/semaglutide...
...combinations with other therapies, in particular the amylin...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...mark. The company is already testing the drug in combination with AM833, an analogue of amylin...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...amylin analog from Boehringer Boehringer has returned to Zealand Pharma A/S (NASDAQ:ZEAL) rights to an amylin...
...to which it holds rights from Zealand under the same 2014 partnership that covered the amylin...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...is expected in 2H20. In an eight-week Phase I trial of AM833, an analogue of amylin...
BioCentury | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

...who has been on the cancer company’s board since 2013, was president and CEO of Amylin Pharmaceuticals Inc....
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...expertise silos,” said Aranout. -- Karen Tkach Tuzman AZ’s diabetes portfolio contains marketed GLP-1R and amylin...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...later due to toxicity seen in the Phase II program. The acquisition of diabetes play Amylin...
...HCV candidate INX-189, which later produced toxicities and was discontinued 6/30/12 - Acquired diabetes company Amylin...
...gave it second-in-class HCV candidate INX-189 from Inhibitex Inc., and a first-in-class diabetes program from Amylin...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

...filings expected in 1H19. The five other obesity programs are all in Phase I: long-acting amylin...
...Byetta exenatide molecule, he said. In addition, he thinks high-dose Ozempic plus AM833, a long-acting amylin...
...weight loss reduction. “We have the high-dose Ozempic and these very interesting combinations, either with amylin...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...cotransporter 1 (SGLT1) Glucose signaling pathway Not expected LX2761 Small molecule Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Amylin...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...trials for the indication, which contain analogs of one or more of the following molecules: amylin...
...he said. Lilly has a about dozen clinical-stage programs in its diabetes pipeline targeting the amylin...
Items per page:
1 - 10 of 1138
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...five obesity programs, Novo pins hopes on amylin/GLP-1...
...for obesity with the pick of an amylin/semaglutide...
...combinations with other therapies, in particular the amylin...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...mark. The company is already testing the drug in combination with AM833, an analogue of amylin...
BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...amylin analog from Boehringer Boehringer has returned to Zealand Pharma A/S (NASDAQ:ZEAL) rights to an amylin...
...to which it holds rights from Zealand under the same 2014 partnership that covered the amylin...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...is expected in 2H20. In an eight-week Phase I trial of AM833, an analogue of amylin...
BioCentury | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

...who has been on the cancer company’s board since 2013, was president and CEO of Amylin Pharmaceuticals Inc....
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...expertise silos,” said Aranout. -- Karen Tkach Tuzman AZ’s diabetes portfolio contains marketed GLP-1R and amylin...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...later due to toxicity seen in the Phase II program. The acquisition of diabetes play Amylin...
...HCV candidate INX-189, which later produced toxicities and was discontinued 6/30/12 - Acquired diabetes company Amylin...
...gave it second-in-class HCV candidate INX-189 from Inhibitex Inc., and a first-in-class diabetes program from Amylin...
BioCentury | Dec 8, 2018
Strategy

Novo gets serious about AI-guided drug design

...filings expected in 1H19. The five other obesity programs are all in Phase I: long-acting amylin...
...Byetta exenatide molecule, he said. In addition, he thinks high-dose Ozempic plus AM833, a long-acting amylin...
...weight loss reduction. “We have the high-dose Ozempic and these very interesting combinations, either with amylin...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...cotransporter 1 (SGLT1) Glucose signaling pathway Not expected LX2761 Small molecule Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Amylin...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...trials for the indication, which contain analogs of one or more of the following molecules: amylin...
...he said. Lilly has a about dozen clinical-stage programs in its diabetes pipeline targeting the amylin...
Items per page:
1 - 10 of 1138